Arqule Inc. buy melinda
Start price
04.05.17
/
50%
€0.90
Target price
10.05.17
€0.99
Performance (%)
-3.51%
End price
10.05.17
€0.87
Summary
This prediction ended on 10.05.17 with a price of €0.87. With a performance of -3.51%, the BUY prediction by melinda finished with a loss. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Arqule Inc. | - | - | - | - |
| iShares Core DAX® | -1,09 % | 0,20 % | 2,09 % | 52,05 % |
| iShares Nasdaq 100 | -2,46 % | -1,79 % | 29,25 % | 84,79 % |
| iShares Nikkei 225® | -5,37 % | -5,43 % | 54,33 % | 69,71 % |
| iShares S&P 500 | -0,20 % | 1,77 % | 23,58 % | 69,52 % |
Comments by melinda for this prediction
In the thread Arqule Inc. diskutieren
intrahepatischen cholangiocarcinoma
hat Einschreibung von Phase 2. Diskussion Post at ASCO am 3. abgeschlossen Juni 2017. Phase 3 für das 3. Quartal 2017 geplant.
(Vom Mitglied beendet)


